TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21889574

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR treatment
Number of subjects: 155
Study: 21890147

Group type: EXPERIMENTAL
Intervention: ≥3 severe pain episodes
Number of subjects: 307

Group type: COMPARATOR
Intervention: <3 severe pain episodes
Number of subjects: 307
Study: 21890206

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (IV NAC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oral N-acetylcysteine (oral NAC)
Number of subjects: 62
Study: 21890336

Group type: EXPERIMENTAL
Intervention: Severe asthma population
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Patients with airflow limitation
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Nonatopics
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Late-onset patients
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Non-eosinophilics
Number of subjects: 74
Study: 21890643

Group type: EXPERIMENTAL
Intervention: Plerixafor (Mozobil, AMD3100)
Number of subjects: 3
Study: 21891874

Group type: EXPERIMENTAL
Intervention: Prone Lachman test
Number of subjects: 52
Study: 21892005

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine (Cervarix®) administered in 3 doses at 0, 1, and 6 months
Number of subjects: 531
Study: 21895032

Group type: EXPERIMENTAL
Intervention: Electrochemotherapy with intravenous bolus injection of bleomycin and electric pulses delivered via long needle electrodes
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Electrochemotherapy procedure
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Number of subjects: 1
Study: 21895536

Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of the oncolytic herpes virus NV1020
Number of subjects: 0
Study: 21897337

Group type: EXPERIMENTAL
Intervention: Total plasma sulfide concentration
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Total plasma sulfide
Number of subjects: 41
Study: 21897775

Group type: EXPERIMENTAL
Intervention: AL Lab (ApneaLINK portable monitor in sleep laboratory)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: AL Home (ApneaLINK portable monitor at home)
Number of subjects: 53

Group type: COMPARATOR
Intervention: PSG (polysomnography)
Number of subjects: 53
Study: 21898376

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg once-daily
Number of subjects: 119
Study: 21900080

Group type: EXPERIMENTAL
Intervention: Echocardiography-estimated elevated pulmonary artery systolic pressure
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: LV lateral E/e' ratio
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Increased hemolysis
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Blood urea nitrogen
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Tricuspid regurgitation velocity
Number of subjects: 483
Study: 21900087

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LGE patterns
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plaque disruption
Number of subjects: 50
Study: 21900113

Group type: EXPERIMENTAL
Intervention: RG7160 (50 to 1,400 mg) administered every week, every 2 weeks, or every 3 weeks
Number of subjects: 75
Study: 21900186

Group type: EXPERIMENTAL
Intervention: CITP
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: PIIINP
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: PIP
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: CITP and PIIINP
Number of subjects: 880
Study: 21900189

Group type: EXPERIMENTAL
Intervention: Thalidomide-dexamethasone (TD) induction therapy and double autotransplantation (ASCT)
Number of subjects: 192
Study: 21900440

Group type: EXPERIMENTAL
Intervention: Honorarium of $2 and a deadline for responding
Number of subjects: 22376

Group type: COMPARATOR
Intervention: Personal invitation alone
Number of subjects: 22376

Group type: EXPERIMENTAL
Intervention: Both recruitment approaches (honorarium and personal invitation)
Number of subjects: 22376
Study: 21901296

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections (3 monthly injections)
Number of subjects: 74
Study: 21903062

Group type: EXPERIMENTAL
Intervention: Midwall fibrosis (n = 54)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Infarct pattern (n = 40)
Number of subjects: 143

Group type: COMPARATOR
Intervention: No LGE (n = 49)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Ejection fraction
Number of subjects: 143
Study: 21903775

Group type: EXPERIMENTAL
Intervention: Purified irradiated PfSPZ administered by needle inoculation in the skin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous immunization of PfSPZ
Number of subjects: 80
Study: 21904098

Group type: EXPERIMENTAL
Intervention: MS-sNT (morphine sulfate and sequestered naltrexone)
Number of subjects: 465
Study: 21904575

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 80

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 80

Group type: COMPARATOR
Intervention: Novel irreversible EGFR TKIs (afatinib, XL647, PF00299804)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed/docetaxel)
Number of subjects: 80
Study: 21906204

Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide (BNP)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Troponin (I or T)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Adrenomedullin (MR-proADM)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: MR-proADM and copeptin (combined)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Natriuretic peptides and troponin (combined)
Number of subjects: 466
Study: 21906302

Group type: EXPERIMENTAL
Intervention: Portion control intervention including dietary counseling and a portion control plate
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care (instructional handouts on diet and exercise)
Number of subjects: 65
Study: 21906756

Group type: EXPERIMENTAL
Intervention: AtriClip device insertion (35, 40, 45, and 50 mm)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: AtriClip device insertion
Number of subjects: 71
Study: 21907540

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (GCBT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Fluoxetine (SSRI)
Number of subjects: 158
Study: 21908707

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Both sexes
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Age range 8 to 40 years
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Gender-specific percentiles
Number of subjects: 407
Study: 21909812

Group type: EXPERIMENTAL
Intervention: Spectral-domain OCT (SD-OCT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Time-domain OCT (TD-OCT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of SD-OCT and TD-OCT
Number of subjects: 50
Study: 21909835

Group type: EXPERIMENTAL
Intervention: Oral and intravenous levetiracetam (LEV)
Number of subjects: 30
Study: 21909986

Group type: EXPERIMENTAL
Intervention: Long-term exercise training and modified food habits
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Baseline PYY levels
Number of subjects: 32
Study: 21911106

Group type: EXPERIMENTAL
Intervention: PCOS women (n=94)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Non-obese PCOS women (BMI<30)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Obese PCOS women (BMI≥30)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Regularly cycling women (control group)
Number of subjects: 94
Study: 21911742

Group type: EXPERIMENTAL
Intervention: VLDL-TG storage in visceral fat
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VLDL-TG storage in upper-body subcutaneous (UBSQ) fat
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VLDL-TG storage in lower-body subcutaneous (LBSQ) fat
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VLDL-TG fractional storage in UBO women in UBSQ fat
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VLDL-TG fractional storage in lean women in visceral fat
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VLDL-TG fractional storage in lean women in LBSQ fat
Number of subjects: 15
Study: 21911779

Group type: EXPERIMENTAL
Intervention: Childhood depressive symptoms assessed using the Children's Depression Inventory at baseline
Number of subjects: 115
Study: 21911781

Group type: EXPERIMENTAL
Intervention: Percutaneous aortic valve replacement (PAVR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: PAVR
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baseline measurements before PAVR
Number of subjects: 11
Study: 21911830

Group type: EXPERIMENTAL
Intervention: Combination of romidepsin, bortezomib, and dexamethasone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Maintenance romidepsin 10 mg/m(2)
Number of subjects: 25
Study: 21911884

Group type: EXPERIMENTAL
Intervention: HMOX1 and UGT1A1 gene promoter variations in chronic HCV patients
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: HMOX1 and UGT1A1 genotype prevalence in pre-cirrhotic and cirrhotic patients
Number of subjects: 146
Study: 21912102

Group type: EXPERIMENTAL
Intervention: Urinary NGAL before nephrectomy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Urinary NGAL after nephrectomy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Urinary KIM-1 before nephrectomy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Urinary KIM-1 after nephrectomy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Correlation of KIM-1 with tumor size
Number of subjects: 122
Study: 21912514

Group type: EXPERIMENTAL
Intervention: Action videogame group (n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non-action videogame group (n=3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crossover control group (n=7)
Number of subjects: 20
Study: 21913066

Group type: EXPERIMENTAL
Intervention: Corticosteroids and immunosuppressors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biologic agents (monoclonal antibodies anti-TNF: infliximab and adalimumab; others: abatacept and tocilizumab)
Number of subjects: 0
Study: 21914165

Group type: EXPERIMENTAL
Intervention: Swedish snus
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 21915260

Group type: EXPERIMENTAL
Intervention: sirolimus, daily for 52 weeks
Number of subjects: 36
Study: 21915479

Group type: EXPERIMENTAL
Intervention: Orbital decompression (16 orbits)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Corticosteroids (6 orbits)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal controls (16 patients, 32 orbits)
Number of subjects: 12
Study: 21915861

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (Havrix™, GlaxoSmithKline Biologicals, Belgium) administered at 1,440 ELISA units (El.U) according to a standard 0, 6 months schedule.
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (Havrix™, GlaxoSmithKline Biologicals, Belgium) administered at 1,440 ELISA units (El.U) according to an extended 0, 12 months schedule.
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Additional dose of HAV vaccine (1,440 El.U) administered to six subjects who had become seronegative for anti-HAV antibodies since year 11.
Number of subjects: 313
Study: 21916630

Group type: EXPERIMENTAL
Intervention: Citalopram (antidepressant medication)
Number of subjects: 301
Study: 21917607

Group type: EXPERIMENTAL
Intervention: Novel therapies targeting tumor stromal elements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 21917625

Group type: EXPERIMENTAL
Intervention: High-dose interleukin-2 (IL-2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-agent interferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of interferon and bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted immunotherapy using immune checkpoint inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted agents (vascular endothelial growth factor and mammalian target of rapamycin pathway inhibitors)
Number of subjects: 0
Study: 21917896

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment with undetectable HIV RNA levels
Number of subjects: 102
Study: 21918235

Group type: EXPERIMENTAL
Intervention: Active recreation sessions in ASP
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Session location and duration
Number of subjects: 240
Study: 21918674

Group type: EXPERIMENTAL
Intervention: Real-time sonography fused with CT for identifying and biopsying liver lesions
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Gastric neuroendocrine carcinoma
Number of subjects: 1
Study: 21920328

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography and tissue Doppler imaging (TDI) measurements
Number of subjects: 15
Study: 21920334

Group type: EXPERIMENTAL
Intervention: T(2)-weighted edema imaging
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Endocardial surface area (ESA)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: APPROACH-score
Number of subjects: 197
Study: 21920781

Group type: EXPERIMENTAL
Intervention: Modified Atkins diet (carbohydrate intake restricted to ten grams/day)
Number of subjects: 15
Study: 21921042

Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline (before hydroxyurea therapy)
Number of subjects: 0
Study: 21921092

Group type: EXPERIMENTAL
Intervention: Homozygosity haplotype analysis weights derived from unique populations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphisms (SNPs) rs12591300 and rs4480740 in FGF7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased lung tissue FGF7 expression
Number of subjects: 0
Study: 21921761

Group type: EXPERIMENTAL
Intervention: Carbon dioxide-based tissue expander with daily administration of small doses of carbon dioxide via a hand-held dosage controller.
Number of subjects: 7
Study: 21921764

Group type: EXPERIMENTAL
Intervention: Computed Tomographic Angiography (CTA)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Magnetic Resonance Angiography (MRA)
Number of subjects: 5
Study: 21923942

Group type: EXPERIMENTAL
Intervention: Postoperative epidural infusion (EI) with ropivacaine 0.2% 3-8 mL/h and fentanyl 2 μg/mL
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min
Number of subjects: 93

Group type: COMPARATOR
Intervention: Intravenous fentanyl 10 μg/ml postoperatively 3-8 mL/h (Control group)
Number of subjects: 93
Study: 21924634

Group type: EXPERIMENTAL
Intervention: Pulse-pressure variation
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pulse-pressure variation >7.69%
Number of subjects: 35
Study: 21925913

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 50
Study: 21926262

Group type: EXPERIMENTAL
Intervention: Absolute myocardial blood flow calculated from (15)O-water PET imaging during adenosine stress
Number of subjects: 104

Group type: COMPARATOR
Intervention: Relative myocardial perfusion images
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Absolute quantification of myocardial blood flow
Number of subjects: 104

Group type: COMPARATOR
Intervention: Relative analysis of myocardial blood flow
Number of subjects: 104
Study: 21926283

Group type: EXPERIMENTAL
Intervention: HIV-infected participants
Number of subjects: 678

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: HIV-infected participants with lipoatrophy
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: HIV-infected participants without lipoatrophy
Number of subjects: 678
Study: 21927046

Group type: EXPERIMENTAL
Intervention: Interventional techniques with safe injection practices and single dose vials for multiple patients
Number of subjects: 3179

Group type: COMPARATOR
Intervention: Interventional techniques with poor hygienic practices
Number of subjects: 3179
Study: 21930103

Group type: EXPERIMENTAL
Intervention: FFR(CT)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Invasive FFR
Number of subjects: 238
Study: 21930612

Group type: EXPERIMENTAL
Intervention: Tenofovir (TFV) 1% vaginal gel
Number of subjects: 16
Study: 21930881

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg by mouth twice daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard dose of oseltamivir
Number of subjects: 21
Study: 21931054

Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple combination cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 21931113

Group type: EXPERIMENTAL
Intervention: Dasatinib induction therapy for 84 days combined with steroids for the first 32 days and intrathecal chemotherapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Dasatinib induction therapy
Number of subjects: 53
Study: 21931593

Group type: EXPERIMENTAL
Intervention: DG100 GPS data logger/receiver
Number of subjects: 0
Study: 21931634

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of E. coli lipopolysaccharide (LPS) 0.3 ng/kg
Number of subjects: 20
Study: 21932952

Group type: EXPERIMENTAL
Intervention: Desirudin (Iprivask®, Canyon Pharmaceuticals™)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous unfractionated heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0
Study: 21933749

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Crizotinib (second-line or third-line setting)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Crizotinib-naive ALK-positive controls
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Crizotinib-treated ALK-positive patients
Number of subjects: 82
Study: 21934054

Group type: EXPERIMENTAL
Intervention: High residual platelet reactivity (HRPR) after clopidogrel loading (≥70% platelet aggregation)
Number of subjects: 1789

Group type: COMPARATOR
Intervention: Low residual platelet reactivity (LRPR) after clopidogrel loading
Number of subjects: 1789

Group type: EXPERIMENTAL
Intervention: HRPR
Number of subjects: 1789

Group type: COMPARATOR
Intervention: LRPR
Number of subjects: 1789
Study: 21934446

Group type: EXPERIMENTAL
Intervention: HIV-seropositive women
Number of subjects: 3744

Group type: COMPARATOR
Intervention: HIV-seronegative women
Number of subjects: 3744
Study: 21935635

Group type: EXPERIMENTAL
Intervention: TSU-68, a multiple tyrosine kinase inhibitor
Number of subjects: 25
Study: 21935916

Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m(2) administered intravenously on days 1 and 8 every 21 days in platinum-resistant cohort
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m(2) administered intravenously on days 1 and 8 every 21 days in platinum-sensitive cohort
Number of subjects: 74
Study: 21937232

Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine
Number of subjects: 293

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 293
Study: 21937277

Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m² intravenously on days 1 and 8 every 3 weeks)
Number of subjects: 128
Study: 21937701

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg/d on days 1-21 of a 28-day cycle
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 38
Study: 21939529

Group type: EXPERIMENTAL
Intervention: NIRS-derived StO₂ initial
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: NIRS-derived StO₂ occlusion slope
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: NIRS-derived StO₂ recovery slope
Number of subjects: 168
Study: 21939939

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 25
Study: 21940776

Group type: EXPERIMENTAL
Intervention: GOLD-2-EP
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: GOLD-4-EP
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Airway Constrictors
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 138
Study: 21940824

Group type: EXPERIMENTAL
Intervention: pegylated E coli asparaginase
Number of subjects: 329

Group type: COMPARATOR
Intervention: native E coli asparaginase
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Erwinia chrysanthemi asparaginase
Number of subjects: 329
Study: 21940838

Group type: EXPERIMENTAL
Intervention: Peginesatide (various doses based on body weight or absolute doses, administered either intravenously or subcutaneously, every 4 or 2 weeks)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Peginesatide (every 4 weeks)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Peginesatide (various doses)
Number of subjects: 139
Study: 21941281

Group type: EXPERIMENTAL
Intervention: Targeting signalling pathways involved in PNI and pain generation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 21941283

Group type: EXPERIMENTAL
Intervention: Recommendations for improving outcomes in ovarian cancer
Number of subjects: 0
Study: 21942531

Group type: EXPERIMENTAL
Intervention: SDP (SUMAVEL DosePro) administered for ≤4 migraine attacks over ≤60 days
Number of subjects: 90
Study: 21942991

Group type: EXPERIMENTAL
Intervention: Theory-based educational intervention targeting nurses' attitudes and knowledge concerning cancer-related pain management.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation of guidelines for systematic daily pain assessments following the educational intervention.
Number of subjects: 0
Study: 21943381

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Patients without psychiatric disorders
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Patients with resolved psychiatric disorders
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Patients with persistent psychiatric disorders
Number of subjects: 127
Study: 21944261

Group type: EXPERIMENTAL
Intervention: Mediterranean-style, low-glycemic-load diet plus medical food (MF) containing phytosterols, soy protein, and extracts from hops and Acacia
Number of subjects: 83

Group type: COMPARATOR
Intervention: Mediterranean-style, low-glycemic-load diet (control group)
Number of subjects: 83